TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Seven Trades on FDA, Clinical Trial Binary Events Mike Havrilla submits:A common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than $1 billion market cap stocks) with pending binary events (e.g. FDA decision or clinical trial results) approximately 3-6 months ahead of the expected catalyst date and sell into the expected upward momentum in both stock price and trading volume.The goal of this bio run-up strategy is to greatly reduce the risk of investment losses by taking profits ahead of the binary event by capitalizing on the expected increase in both stock price and volume as more short-term momentum and day traders become active, which typically occurs at about 2-3 weeks out from the catalyst date and results in extreme price volatility and intraday swings. Click on the preceding link for a website describing this strategy in greater detail and click here for a link to a YouTube video at my website outlining the same.Complete Story » seekingalpha.com |
Myriad Pharmaceuticals: A Value Investor's Dream Joseph Krueger submits: Recent market volatility has really beaten down some biotech stocks, and I have been going on a shopping spree. One stock which is showing a clear reversal in my opinion is Myriad Pharmaceuticals (MYRX). Although I know of the company, I had not been following it until it came up on a technical screen last week. From a technical perspective, a rebound has started and there is still plenty of recovery to go in my opinion. What surprised me about Myriad was how low its current market valuation is right now. Myriad’s current capitalization is less than $100 million, even though it has over $150 million in cash, and no significant liabilities. Mystified as to why MYRX would be trading at a 40% discount to the net value of all its assets (95% of which is cash), I took a good hard look at the company, and learned about the mishaps of MYRX management, and the current reorganization, which have surely contributed to the fall of MYRX stock value. However, probing deeper, it seems to me that the market is overreacting to these events. I see nothing that justifies the company trading at about 60% of its net cash value. MYRX still has a viable oncology clinical program, and can continue to leverage its large cash position to develop this program, or pursue a profitable merger as it has attempted in the past. Right now, short sighted investors are focusing on criticizing management rather than accumulating shares which trade for pennies on the dollar, in real cash value. The big question is: How did this happen? To understand how MYRX is trading at such as discount, I had to look at its (brief) history: In mid 2009, molecular diagnostic giant Myriad Genetics (MYGN) separated its molecular diagnostic business from its research and drug development businesses through the spin-off of Myriad Pharmaceuticals. Myriad Genetics contributed substantially all of its research and drug development businesses and about $190 million of cash and marketable securities to Myriad Pharmaceuticals, and distributed this spin-off to shareholders as a dividend of one share of Myriad Pharmaceutical common stock for every four shares of Myriad Genetics common stock (I will refer to Myriad Pharmaceuticals as MYRX in the future to avoid confusion with Myriad Genetics).Complete Story » seekingalpha.com |
China Sets Conditions on Novartis Deal China approved Novartis's acquisition of Alcon, but attached conditions to the deal in the China market. online.wsj.com |
Covance to Present at Morgan Stanley Global Healthcare Conference [PR Newswire] - Covance Inc. today announced that it will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 14, 2010 at 2:10 p.m. ET. Â Investors may access a live webcast of the presentation at www.covance.com. Â In order to register and download any necessary software, please log on 10 minutes early. us.rd.yahoo.com |
Amgen Q3 2010 Earnings Call Transcript Amgen (AMGN)Q3 2010 Earnings CallOctober 25, 2010 5:00 pm ETComplete Story » seekingalpha.com |